Conv. Plasma
Nigella Sativa

All remdesivir studies
Meta analysis
study COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Case report study of the first five COVID-19 patients treated with remdesivir in France

Dubert et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.093
Jun 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Early report on 5 ICU patients treated with remdesivir highlighting issues with usage in critically ill patients.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
Dubert et al., 30 Jun 2020, peer-reviewed, 15 authors.
This PaperRemdesivirAll
Case report study of the first five COVID-19 patients treated with remdesivir in France
Marie Dubert, Benoit Visseaux, Valentina Isernia, Lila Bouadma, Laurène Deconinck, Juliette Patrier, Paul-Henri Wicky, Diane Le Pluart, Laura Kramer, Christophe Rioux, Quentin Le Hingrat, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Jade Ghosn, Francois-Xavier Lescure
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.093
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-
Author contributions All authors have read and approved the manuscript. MD, VI, YY, JG, and XL wrote the manuscript and took care of the patients in the infectious and tropical diseases department. LD, DLP, and CR took care of the patients in the infectious and tropical diseases department. BV participated to the virological tests and wrote the manuscript. QLH and NHF participated in the virological tests. LB, JP, and PHW took care of the patients in the medical and infectious intensive care unit. LK assisted in obtaining and dispensing the drug. Consent for publication The Institutional Review Board of Bichat-Claude Bernard University Hospital approved this report and waived the need for informed consent from individual patients, due to the retrospective chart review design and absence of identifying images or personal/clinical details that could compromise anonymity. Conflict of interest The authors declare that they have no competing interests.
Arabi, Asiri, Assiri, Jokhdar, Alothman et al., Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial, Trials
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv
Chu, Cheng, Hung, Wong, Chan et al., Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax
Corman, Bleicker, Brunink, Drosten, Diagnostic detection of 2019-nCoV by real-time RT-PCR -protocol and preliminary evaluation as of Jan 17
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Holshue, Debolt, Lindquist, Lofy, Wiesman et al., First case of 2019 novel coronavirus in the United States, N Engl J Med
Kujawski, Wong, Collins, Epstein, Killerby et al., First 12 patients with coronavirus disease 2019 (COVID-19) in the United States
Lescure, Bouadma, Nguyen, Parisey, Wicky et al., Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Infect Dis
Martinez, Compounds with therapeutic potential against novel respiratory 2019 coronavirus, Antimicrob Agents Chemother
Mulangu, Dodd, Davey, Mbaya, Proschan et al., A randomized, controlled trial of ebola virus disease therapeutics, N Engl J Med
Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, Lancet Infect Dis
Sheahan, Sims, Graham, Menachery, Gralinski et al., Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res 2020a
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop